MedTrace Logo

Use Of Oral Itraconazole In Patients With Locally Limited Basocellular Carcinoma Of Skin.

NCT03972748 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2019-06-04

No results posted yet for this study

Summary

Patients with localized basocellular carcinoma of the skin, will receive oral Itraconazole, 200 mg twice daily, for 60 days, prior to curative intent surgery.

Conditions

Interventions

DRUG

Itraconazole 200 mg

Oral Itraconazole capsules, 200 mg, twice daily, for 60 days prior to surgery with curative intent.

Sponsors & Collaborators

  • Hospital de Clinicas de Porto Alegre

    lead OTHER

Principal Investigators

  • Renato M Bakos, Ph. D. · Hospital de Clinicas de Porto Alegre

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-01-05
Primary Completion
2020-12-01
Completion
2021-06-01

Countries

  • Brazil

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03972748 on ClinicalTrials.gov